Indaptus Therapeutics (INDP) Liabilities and Shareholders Equity (2020 - 2026)
Indaptus Therapeutics (INDP) posted quarterly Liabilities and Shareholders Equity of $2.2 million for Q1 2026, down 59.7% year-over-year from $5.4 million in Q1 2025, and down 76.58% quarter-over-quarter from $9.3 million in Q4 2025.
Indaptus Therapeutics (INDP) Liabilities and Shareholders Equity (2020 - 2026) Analysis & Trends
Indaptus Therapeutics' Liabilities and Shareholders Equity history runs 7 years deep, the most recent figure standing at $2.2 million for Q1 2026.
- In Q1 2026, Liabilities and Shareholders Equity fell 59.7% year-over-year to $2.2 million; the TTM figure through Mar 2026 stood at $25.2 million (down 13.54% YoY), while the FY2025 annual figure was $9.3 million, up 26.86% from the prior year.
- Liabilities and Shareholders Equity for Q1 2026 stood at $2.2 million, down from $9.3 million in the prior quarter.
- The five-year high for Liabilities and Shareholders Equity was $37.1 million in Q1 2022, with the low at $2.2 million in Q1 2026.
- The 5-year median for Liabilities and Shareholders Equity is $10.9 million (2024), against an average of $16.0 million.
- The sharpest annual moves came in 2022 and 2024: Liabilities and Shareholders Equity surged 112.77% in 2022, then tumbled 61.04% in 2024.
- Indaptus Therapeutics' Liabilities and Shareholders Equity stood at $28.1 million in 2022, then sank by 46.82% to $14.9 million in 2023, then tumbled by 50.83% to $7.3 million in 2024, then rose by 26.86% to $9.3 million in 2025, then tumbled by 76.58% to $2.2 million in 2026.
- Business Quant data shows INDP's Liabilities and Shareholders Equity at $2.2 million in Q1 2026, $9.3 million in Q4 2025, and $6.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 10.03 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 10.96 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 9.18 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 5.56 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 25.60 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 2.10 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 19.82 Bn |
| 10 | Indaptus Therapeutics | 146.91 Mn | 135.35 Mn | - | 11.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 11.99 Mn |
| Mar 31, 2026 | 2.18 Mn |
| Dec 31, 2025 | 9.31 Mn |
| Sep 30, 2025 | 6.84 Mn |
| Jun 30, 2025 | 6.84 Mn |
| Mar 31, 2025 | 5.41 Mn |
| Dec 31, 2024 | 7.34 Mn |
| Sep 30, 2024 | 8.24 Mn |
| Jun 30, 2024 | 8.12 Mn |
| Mar 31, 2024 | 10.95 Mn |
| Dec 31, 2023 | 14.92 Mn |
| Sep 30, 2023 | 17.79 Mn |
| Jun 30, 2023 | 20.84 Mn |
| Mar 31, 2023 | 23.14 Mn |
| Dec 31, 2022 | 28.06 Mn |
| Sep 30, 2022 | 30.45 Mn |
| Jun 30, 2022 | 34.06 Mn |
| Mar 31, 2022 | 37.09 Mn |
| Dec 31, 2021 | 40.58 Mn |
| Sep 30, 2021 | 43.86 Mn |